VolitionRX Ltd
Closed
2.34 1.3
Overview
Share price change
24h
Min
2.1
Max
2.34
Income | -924K -6.3M |
|---|---|
Sales | -180K 447K |
EPS | -0.051 |
Profit margin | -1,409.924 |
Employees | 75 |
EBITDA | -724K -5M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +1624.14% upside |
Next Earnings | 14 May 2026 |
|---|
Market Cap | 17M |
|---|---|
Previous open | 1.04 |
Previous close | 2.34 |
VolitionRX Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
VolitionRX Ltd Forecast
Price Target
By TipRanks
1624.14% upside
12 Months Forecast
Average 40 USD 1624.14%
High 60 USD
Low 20 USD
Based on 3 Wall Street analysts offering 12 month price targets forVolitionRX Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About VolitionRX Ltd
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
